Takeda EGFRex20 Inhibitor
EGFR exon 20 mutant inhibitor, oral once-daily Breakthrough Therapy for ex20+ NSCLC (Ph. I) from cellular screening + SBDD mobocertinib ARIAD/Takeda, Cambridge, MA
Molecules of the Month - 2021 Molecules of the Year Nominees
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader
- Pfizer CoV-2 MPro Inhibitor
- Arvinas ER Chimeric Degrader
- Kronos CDK9 Inhibitor
- Merck PCSK9 Inhibitors
- Mirati KRASG12D Inhibitor
- Takeda EGFRex20 Inhibitor
- Lilly GLP Molecular Glue
- RevMed KRASG12C Tricomplex Inhibitor
- Genentech mPI3Kα Degrader
- H3Bio SF3b Splicing Modulator
- BioCryst Kallikrein Inhibitor
- Genentech ER Degrader